Discover 227 paid clinical trials in Sioux Falls, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 227
Active & Responsive
Helix Research Network
for
Genetic Predisposition to Disease, Genetics Disease
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Location: Sioux Falls SD, Madison WI, Aurora CO, Ann Arbor MI,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT05458297
Phase2, Recruiting
Active & Responsive
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
for
Endometrial Cancer
Location: Sioux Falls SD, Maple Grove MN, Cincinnati OH,
Sponsor: Faeth Therapeutics
Sex: Female
Age: 18+
Code: NCT06463028
Phase2, Recruiting
Active & Responsive
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
for
Non-small Cell Lung Cancer (NSCLC)
Location: Sioux Falls SD, Fargo ND, Springfield MO, Ann Arbor MI,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06305754
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Location: Sioux Falls SD, Aurora CO, Oklahoma City OK,
Sponsor: Eisai Inc.
Sex: All
Age: 18+
Code: NCT04008797
Phase1, Phase2, Recruiting
Active & Responsive
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)